Cancer microenvironment and pharmacological interventions.
- Published in:
- British Journal of Pharmacology, 2024, v. 181, n. 2, p. 213, doi. 10.1111/bph.16279
- By:
- Publication type:
- Article
Works matching IS 00071188 AND DT 2024 AND VI 181 AND IP 2
Results: 8
1
2
Understanding the interaction between leukaemia stem cells and their microenvironment to improve therapeutic approaches.
- Published in:
- British Journal of Pharmacology, 2024, v. 181, n. 2, p. 273, doi. 10.1111/bph.16162
- By:
- Publication type:
- Article
3
Targeting integrins in drug‐resistant acute myeloid leukaemia.
- Published in:
- British Journal of Pharmacology, 2024, v. 181, n. 2, p. 295, doi. 10.1111/bph.16149
- By:
- Publication type:
- Article
4
Issue Information.
- Published in:
- British Journal of Pharmacology, 2024, v. 181, n. 2, p. 211, doi. 10.1111/bph.16117
- Publication type:
- Article
5
Optimization of cancer immunotherapy on the basis of programmed death ligand‐1 distribution and function.
- Published in:
- British Journal of Pharmacology, 2024, v. 181, n. 2, p. 257, doi. 10.1111/bph.16054
- By:
- Publication type:
- Article
6
Stromal bone marrow fibroblasts and mesenchymal stem cells support acute myeloid leukaemia cells and promote therapy resistance.
- Published in:
- British Journal of Pharmacology, 2024, v. 181, n. 2, p. 216, doi. 10.1111/bph.16028
- By:
- Publication type:
- Article
7
Micro‐environment alterations through time leading to myeloid malignancies.
- Published in:
- British Journal of Pharmacology, 2024, v. 181, n. 2, p. 283, doi. 10.1111/bph.15924
- By:
- Publication type:
- Article
8
Mesenchymal stem cells and cancer‐associated fibroblasts as a therapeutic strategy for breast cancer.
- Published in:
- British Journal of Pharmacology, 2024, v. 181, n. 2, p. 238, doi. 10.1111/bph.15861
- By:
- Publication type:
- Article